Loading
BIRC5 (Baculoviral IAP repeat-containing protein 5) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer and HER2-positive breast cancer.
Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis. Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis. Acts as an important regulator of the localisation of this complex; directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organisation of the centre spindle by associating with polymerised microtubules.
CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Trastuzumab, Platinum Compound and Taxane Compound.
In plain words · BIRC5 (Baculoviral IAP repeat-containing protein 5) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer and HER2-positive breast cancer.
BIRC5 (Baculoviral IAP repeat-containing protein 5) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer and HER2-positive breast cancer.
Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis.
No product in this corpus aims at BIRC5 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Broadly expressed or essential: HPA lists BIRC5 among essential proteins; a medicine acting on the wild-type protein would expose normal tissue too. HPA BIRC5: RNA tissue enhanced (bone marrow 36 nTPM, lymphoid tissue 38 nTPM, testis 19 nTPM); blood lineage lineage enriched (T-cells 14 nTPM); high antibody staining in 1 normal tissue; highest cancer staining testis cancer (2 of 12 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lung cancer (all types), Breast cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas BIRC5 tissue; Open Targets ENSG00000089685 associations
First described 1997. Earliest sequence paper UniProt cites for the protein: Ambrosini et al, Nat. Med, 1997, "A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma". Source.
Sources: HGNC HGNC:593 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O15392 (protein name, function text, keywords and locations (REST API)); CIViC gene BIRC5 (2 evidence items, 0 assertions, 2 variants; diseases: Lung Non-small Cell Carcinoma, HER2 Positive Breast Cancer (GraphQL API, CC0))
Multitasking protein that has dual roles in promoting cell proliferation and preventing apoptosis. Component of a chromosome passage protein complex (CPC) which is essential for chromosome alignment and segregation during mitosis and cytokinesis. Acts as an important regulator of the localisation of this complex; directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organisation of the centre spindle by associating with polymerised microtubules. Involved in the recruitment of CPC to centromeres during early mitosis via association with histone H3 phosphorylated at 'Thr-3' (H3pT3) during mitosis. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. May counteract a default induction of apoptosis in G2/M phase. Location: Cytoplasm; Nucleus; Chromosome; Chromosome, centromere (UniProt). Locus 17q25.3 (HGNC).
RNA: tissue enhanced (bone marrow 36 nTPM, lymphoid tissue 38 nTPM, testis 19 nTPM), detected in many normal tissues. Blood: lineage enriched (T-cells 14 nTPM).
Medium: Bone marrow, Esophagus, Lymph node, Oral mucosa, Placenta, Skin, Tonsil, Vagina.
Medium only: carcinoid, endometrial cancer, lung cancer, lymphoma.
HPA BIRC5 tissue · HPA BIRC5 pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"BIRC5" OR ABSTRACT:"BIRC5" OR TITLE:"baculoviral IAP repeat containing 5" OR ABSTRACT:"baculoviral IAP repeat containing 5" OR TITLE:"Baculoviral IAP repeat-containing protein 5" OR ABSTRACT:"Baculoviral IAP repeat-containing protein 5" OR TITLE:"EPR-1" OR ABSTRACT:"EPR-1" OR TITLE:"survivin" OR ABSTRACT:"survivin" OR TITLE:"API4" OR ABSTRACT:"API4") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BIRC5, not a curated reading list.